Cidara Therapeutics, Inc.
CDTX
$20.69
$1.256.40%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -1,527.98% | -75.52% | -- | -442.71% | 81.28% |
| Total Depreciation and Amortization | 51.28% | 177.27% | -- | 75.00% | 34.48% |
| Total Amortization of Deferred Charges | -100.00% | -100.00% | -- | -96.63% | 101.35% |
| Total Other Non-Cash Items | 78.96% | 0.00% | -- | 10.75% | 27.97% |
| Change in Net Operating Assets | 295.59% | -441.73% | -- | 117.04% | -261.08% |
| Cash from Operations | -131.21% | -2,145.72% | -- | 39.03% | 39.42% |
| Capital Expenditure | 100.00% | 15.87% | -- | 75.53% | -1,877.78% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 100.00% | 15.87% | -- | 75.53% | -1,877.78% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,228,412.50% | -- | -- | -- | -98.80% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1,227,462.50% | -- | -- | -100.35% | -98.80% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 633.59% | -2,001.31% | -- | -144.34% | 36.64% |